

Peer Review File

Article information: <https://dx.doi.org/10.21037/tcr-2025-153>

Reviewer A

This article presents the results of a study on the role of PRTN3 protein in the development of gastric cancer. The authors found that a low level of PRTN3 expression is associated with the progression of the disease, as well as with suppression of the cell cycle and stimulation of apoptosis.

The results of this study may have important practical implications for the development of new approaches to the treatment of gastric cancer. Understanding the mechanisms that regulate disease progression can help create more effective therapies.

One of the possible areas of application of the obtained data is the development of new drugs aimed at increasing the level of PRTN3 expression or blocking its negative effect on the cell cycle and apoptosis. This may lead to improved treatment outcomes for patients with stomach cancer.

In addition, the results of the study may contribute to the development of new methods for diagnosing stomach cancer. For example, analysis of the level of PRTN3 expression in tumor tissues can help in determining the risk of disease progression and in choosing the most appropriate treatment method.

Reviewer B

I reviewed the article entitled "Low expression of PRTN3 regulates the progression of gastric cancer by inhibition of cell cycle and promotion of apoptosis". The article is well described and the research is interesting and deserves publication, however there are points that need adjustments.

Comment 1: The conclusion of the abstract is adequate, however, the final conclusion of the original article seems to be different from the conclusion of the abstract.

Reply 1: Thank you for your valuable suggestion. We have modified the conclusion section of the abstract to include this sentence: “ **high expression of PRTN3 is associated with GC tumor N staging.** ” In addition, in the conclusion at the end of the article, the word “resulting” has been replaced with “**stimulating**”.

Changes in the text: We have modified our text as advised (see Page2, line 53-54) and (see Page13, line 424)

Comment 2. In the Introduction, where it is mentioned that Treatment approaches including radiotherapeutic, immunotherapeutic, targeted, and chemotherapeutic interventions can all achieve some degree of efficacy in GC management, the authors forgot to mention surgical treatment.

Reply 2: Thank you very much for the comments. We have added this element of **surgical treatment** to the newly submitted manuscript.

Changes in the text: We have modified our text as advised (see Page3, line 84).

Comment 3. Conflicts of Interest. I see no need to mention that MPSA receives payment from Libbs for the writing of an educational material about the role of Bevacizumab in the conversion therapy of colorectal cancer liver metastasis, as there is no relation to the article described.

Reply 3: Thank you for your constructive comment. We have removed the statement about conflicts of interest from the manuscript and revised it to read: “The authors declare that they have no competing interests.”

Changes in the text: We have modified our text as advised (see Page14, line 440-441).